Pharmacology >
Anticoagulant > Slide Presentations

No Title Presenter Date
18 Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS Roxana Mehran Jul. 21. 09
17 Perspectives on the Use of Fondaparinux in ACS: Transitioning to the Cath Lab Ron Waksman Jul. 21. 09
16 MULTI-STRATEGY: Tirofiban vs. Abciximab During Primary PCI in STEMI Marco Valgimigli Jul. 21. 09
15 ON-TIME-2: Early Administration of Tirofiban During Primary PCI in STEMI Harry Suryapranata Jul. 21. 09
14 ATLAS-TIMI Jan. 07. 09
13 Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI Charles A. Simonton Nov. 02. 07
12 Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible Gregg W. Stone Nov. 02. 07
11 Pushing the Envelope for Bivalirudin Monotherapy: Design, Rationale, and Status of ISARREACT-4 and HORIZONS Adnan Kastrati Nov. 02. 07
10 Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data Gregg W. Stone Sep. 14. 07
9 Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI Charles A. Simonton Sep. 14. 07
8 Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4 Adnan Kastrati Sep. 14. 07
7 ACUITY: One Year Outcome of ACUITY Trial Roxana Mehran May. 25. 07
6 ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results Gregg W. Stone May. 25. 07
5 Lipid Treatment in Post PCI Patients Dong Hoon Choi Nov. 10. 06
4 Tirofiban and STEMI Management: A Future Perspective Gian B. Danzi Oct. 13. 06
CardioVascular Research Foundation (CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
Tel_82.2.3010.4792 | Fax_82.2.475.6898
재단법인 심장혈관연구재단
대표이사 박승정 | 서울시 송파구 올림픽로43길 88, 서울아산병원 아산교육연구관 2층 | 사업자등록번호 215-82-06387
개인정보 관리책임자_노순정 | 전화번호_02.3010.4792 | 팩스번호_02.475.6898
Copyright © CVRF, Seoul, Korea. All rights reserved.